Viewing Study NCT05921760


Ignite Creation Date: 2025-12-25 @ 2:15 AM
Ignite Modification Date: 2026-01-07 @ 10:46 AM
Study NCT ID: NCT05921760
Status: COMPLETED
Last Update Posted: 2025-07-15
First Post: 2023-04-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
Sponsor: Servier Bio-Innovation LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module